The NINDS Parkinson's disease biomarkers program

Liana S. Rosenthal, Daniel Drake, Roy N. Alcalay, Debra Babcock, F. Dubois Bowman, Alice Chen-Plotkin, Ted M. Dawson, Richard B. Dewey, Dwight C. German, Xuemei Huang, Barry Landin, Matthew Mcauliffe, Vladislav A. Petyuk, Clemens R. Scherzer, Coryse St Hillaire-Clarke, Beth Anne Sieber, Margaret Sutherland, Chi Tarn, Andrew West, David VaillancourtJing Zhang, Katrina Gwinn

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Background: Neuroprotection for Parkinson's disease (PD) remains elusive. Biomarkers hold the promise of removing roadblocks to therapy development. The National Institute of Neurological Disorders and Stroke has therefore established the Parkinson's Disease Biomarkers Program to promote discovery of PD biomarkers for use in phase II and III clinical trials. Methods: Using a novel consortium design, the Parkinson's Disease Biomarker Program is focused on the development of clinical and laboratory-based biomarkers for PD diagnosis, progression, and prognosis. Standardized operating procedures and pooled reference samples were created to allow cross-project comparisons and assessment of batch effects. A web-based Data Management Resource facilitates rapid sharing of data and biosamples across the research community for additional biomarker projects. Results: Eleven consortium projects are ongoing, seven of which recruit participants and obtain biosamples. As of October 2014, 1,082 participants have enrolled (620 PD, 101 with other causes of parkinsonism, 23 essential tremor, and 338 controls), 1,040 of whom have at least one biosample. Six thousand eight hundred ninety-eight total biosamples are available from baseline, 6-, 12-, and 18-month visits: 1,006 DNA, 1,661 RNA, 1,419 whole blood, 1,382 plasma, 1,200 serum, and 230 cerebrospinal fluid (CSF). Quality control analysis of plasma, serum, and CSF samples indicates that almost all samples are high quality (24 of 2,812 samples exceed acceptable hemoglobin levels). Conclusions: By making samples and data widely available, using stringent operating procedures based on existing standards, hypothesis testing for biomarker discovery, and providing a resource that complements existing programs, the Parkinson's Disease Biomarker Program will accelerate the pace of PD biomarker research.

Original languageEnglish (US)
JournalMovement Disorders
DOIs
StateAccepted/In press - 2015

Fingerprint

National Institute of Neurological Disorders and Stroke
Parkinson Disease
Biomarkers
Cerebrospinal Fluid
Essential Tremor
Phase III Clinical Trials
Phase II Clinical Trials
Information Dissemination
Parkinsonian Disorders
Serum
Research
Quality Control
Disease Progression
Hemoglobins
RNA

Keywords

  • Biofluids
  • Data management
  • Disease-modifying strategies
  • Parkinsonism

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Rosenthal, L. S., Drake, D., Alcalay, R. N., Babcock, D., Bowman, F. D., Chen-Plotkin, A., ... Gwinn, K. (Accepted/In press). The NINDS Parkinson's disease biomarkers program. Movement Disorders. https://doi.org/10.1002/mds.26438

The NINDS Parkinson's disease biomarkers program. / Rosenthal, Liana S.; Drake, Daniel; Alcalay, Roy N.; Babcock, Debra; Bowman, F. Dubois; Chen-Plotkin, Alice; Dawson, Ted M.; Dewey, Richard B.; German, Dwight C.; Huang, Xuemei; Landin, Barry; Mcauliffe, Matthew; Petyuk, Vladislav A.; Scherzer, Clemens R.; Hillaire-Clarke, Coryse St; Sieber, Beth Anne; Sutherland, Margaret; Tarn, Chi; West, Andrew; Vaillancourt, David; Zhang, Jing; Gwinn, Katrina.

In: Movement Disorders, 2015.

Research output: Contribution to journalArticle

Rosenthal, LS, Drake, D, Alcalay, RN, Babcock, D, Bowman, FD, Chen-Plotkin, A, Dawson, TM, Dewey, RB, German, DC, Huang, X, Landin, B, Mcauliffe, M, Petyuk, VA, Scherzer, CR, Hillaire-Clarke, CS, Sieber, BA, Sutherland, M, Tarn, C, West, A, Vaillancourt, D, Zhang, J & Gwinn, K 2015, 'The NINDS Parkinson's disease biomarkers program', Movement Disorders. https://doi.org/10.1002/mds.26438
Rosenthal LS, Drake D, Alcalay RN, Babcock D, Bowman FD, Chen-Plotkin A et al. The NINDS Parkinson's disease biomarkers program. Movement Disorders. 2015. https://doi.org/10.1002/mds.26438
Rosenthal, Liana S. ; Drake, Daniel ; Alcalay, Roy N. ; Babcock, Debra ; Bowman, F. Dubois ; Chen-Plotkin, Alice ; Dawson, Ted M. ; Dewey, Richard B. ; German, Dwight C. ; Huang, Xuemei ; Landin, Barry ; Mcauliffe, Matthew ; Petyuk, Vladislav A. ; Scherzer, Clemens R. ; Hillaire-Clarke, Coryse St ; Sieber, Beth Anne ; Sutherland, Margaret ; Tarn, Chi ; West, Andrew ; Vaillancourt, David ; Zhang, Jing ; Gwinn, Katrina. / The NINDS Parkinson's disease biomarkers program. In: Movement Disorders. 2015.
@article{d888aadde3854eb4a80555681161bc35,
title = "The NINDS Parkinson's disease biomarkers program",
abstract = "Background: Neuroprotection for Parkinson's disease (PD) remains elusive. Biomarkers hold the promise of removing roadblocks to therapy development. The National Institute of Neurological Disorders and Stroke has therefore established the Parkinson's Disease Biomarkers Program to promote discovery of PD biomarkers for use in phase II and III clinical trials. Methods: Using a novel consortium design, the Parkinson's Disease Biomarker Program is focused on the development of clinical and laboratory-based biomarkers for PD diagnosis, progression, and prognosis. Standardized operating procedures and pooled reference samples were created to allow cross-project comparisons and assessment of batch effects. A web-based Data Management Resource facilitates rapid sharing of data and biosamples across the research community for additional biomarker projects. Results: Eleven consortium projects are ongoing, seven of which recruit participants and obtain biosamples. As of October 2014, 1,082 participants have enrolled (620 PD, 101 with other causes of parkinsonism, 23 essential tremor, and 338 controls), 1,040 of whom have at least one biosample. Six thousand eight hundred ninety-eight total biosamples are available from baseline, 6-, 12-, and 18-month visits: 1,006 DNA, 1,661 RNA, 1,419 whole blood, 1,382 plasma, 1,200 serum, and 230 cerebrospinal fluid (CSF). Quality control analysis of plasma, serum, and CSF samples indicates that almost all samples are high quality (24 of 2,812 samples exceed acceptable hemoglobin levels). Conclusions: By making samples and data widely available, using stringent operating procedures based on existing standards, hypothesis testing for biomarker discovery, and providing a resource that complements existing programs, the Parkinson's Disease Biomarker Program will accelerate the pace of PD biomarker research.",
keywords = "Biofluids, Data management, Disease-modifying strategies, Parkinsonism",
author = "Rosenthal, {Liana S.} and Daniel Drake and Alcalay, {Roy N.} and Debra Babcock and Bowman, {F. Dubois} and Alice Chen-Plotkin and Dawson, {Ted M.} and Dewey, {Richard B.} and German, {Dwight C.} and Xuemei Huang and Barry Landin and Matthew Mcauliffe and Petyuk, {Vladislav A.} and Scherzer, {Clemens R.} and Hillaire-Clarke, {Coryse St} and Sieber, {Beth Anne} and Margaret Sutherland and Chi Tarn and Andrew West and David Vaillancourt and Jing Zhang and Katrina Gwinn",
year = "2015",
doi = "10.1002/mds.26438",
language = "English (US)",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - The NINDS Parkinson's disease biomarkers program

AU - Rosenthal, Liana S.

AU - Drake, Daniel

AU - Alcalay, Roy N.

AU - Babcock, Debra

AU - Bowman, F. Dubois

AU - Chen-Plotkin, Alice

AU - Dawson, Ted M.

AU - Dewey, Richard B.

AU - German, Dwight C.

AU - Huang, Xuemei

AU - Landin, Barry

AU - Mcauliffe, Matthew

AU - Petyuk, Vladislav A.

AU - Scherzer, Clemens R.

AU - Hillaire-Clarke, Coryse St

AU - Sieber, Beth Anne

AU - Sutherland, Margaret

AU - Tarn, Chi

AU - West, Andrew

AU - Vaillancourt, David

AU - Zhang, Jing

AU - Gwinn, Katrina

PY - 2015

Y1 - 2015

N2 - Background: Neuroprotection for Parkinson's disease (PD) remains elusive. Biomarkers hold the promise of removing roadblocks to therapy development. The National Institute of Neurological Disorders and Stroke has therefore established the Parkinson's Disease Biomarkers Program to promote discovery of PD biomarkers for use in phase II and III clinical trials. Methods: Using a novel consortium design, the Parkinson's Disease Biomarker Program is focused on the development of clinical and laboratory-based biomarkers for PD diagnosis, progression, and prognosis. Standardized operating procedures and pooled reference samples were created to allow cross-project comparisons and assessment of batch effects. A web-based Data Management Resource facilitates rapid sharing of data and biosamples across the research community for additional biomarker projects. Results: Eleven consortium projects are ongoing, seven of which recruit participants and obtain biosamples. As of October 2014, 1,082 participants have enrolled (620 PD, 101 with other causes of parkinsonism, 23 essential tremor, and 338 controls), 1,040 of whom have at least one biosample. Six thousand eight hundred ninety-eight total biosamples are available from baseline, 6-, 12-, and 18-month visits: 1,006 DNA, 1,661 RNA, 1,419 whole blood, 1,382 plasma, 1,200 serum, and 230 cerebrospinal fluid (CSF). Quality control analysis of plasma, serum, and CSF samples indicates that almost all samples are high quality (24 of 2,812 samples exceed acceptable hemoglobin levels). Conclusions: By making samples and data widely available, using stringent operating procedures based on existing standards, hypothesis testing for biomarker discovery, and providing a resource that complements existing programs, the Parkinson's Disease Biomarker Program will accelerate the pace of PD biomarker research.

AB - Background: Neuroprotection for Parkinson's disease (PD) remains elusive. Biomarkers hold the promise of removing roadblocks to therapy development. The National Institute of Neurological Disorders and Stroke has therefore established the Parkinson's Disease Biomarkers Program to promote discovery of PD biomarkers for use in phase II and III clinical trials. Methods: Using a novel consortium design, the Parkinson's Disease Biomarker Program is focused on the development of clinical and laboratory-based biomarkers for PD diagnosis, progression, and prognosis. Standardized operating procedures and pooled reference samples were created to allow cross-project comparisons and assessment of batch effects. A web-based Data Management Resource facilitates rapid sharing of data and biosamples across the research community for additional biomarker projects. Results: Eleven consortium projects are ongoing, seven of which recruit participants and obtain biosamples. As of October 2014, 1,082 participants have enrolled (620 PD, 101 with other causes of parkinsonism, 23 essential tremor, and 338 controls), 1,040 of whom have at least one biosample. Six thousand eight hundred ninety-eight total biosamples are available from baseline, 6-, 12-, and 18-month visits: 1,006 DNA, 1,661 RNA, 1,419 whole blood, 1,382 plasma, 1,200 serum, and 230 cerebrospinal fluid (CSF). Quality control analysis of plasma, serum, and CSF samples indicates that almost all samples are high quality (24 of 2,812 samples exceed acceptable hemoglobin levels). Conclusions: By making samples and data widely available, using stringent operating procedures based on existing standards, hypothesis testing for biomarker discovery, and providing a resource that complements existing programs, the Parkinson's Disease Biomarker Program will accelerate the pace of PD biomarker research.

KW - Biofluids

KW - Data management

KW - Disease-modifying strategies

KW - Parkinsonism

UR - http://www.scopus.com/inward/record.url?scp=84949871151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949871151&partnerID=8YFLogxK

U2 - 10.1002/mds.26438

DO - 10.1002/mds.26438

M3 - Article

C2 - 26442452

AN - SCOPUS:84949871151

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

ER -